Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Multiple pathways contribute to the pathogenesis of atopic dermatitis (AD), and various targeted topical, biologic, and oral systemic agents have subsequently been developed. This review examines the mechanism of action and study designs of agents that have failed trials for AD to identify lessons that may shed light on reasons for their failure. Clinicaltrials.gov was searched for completed, placebo-controlled phase II and III studies assessing agents for AD that did not meet the primary endpoint, specifically reduction of AD severity. PubMed was then searched for further data on the agents identified with known mechanism of actions. Only phase II trials met inclusion criteria. Analyses of the mechanisms of action, study design, and patient demographics of the failed clinical trials for the following agents are presented: apremilast and roflumilast (PDE-4 inhibitors), fevipiprant and temapiprant (CRTH2 inhibitors), and tezepelumab and ustekinumab (monoclonal antibodies). Agents that did not meet their trial endpoints for AD may still hold therapeutic value in certain subpopulation groups or other diseases. Validating phase II trials based off subgroup analyses from previous trials may be warranted as our understanding of the pathophysiology of AD continues to grow.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is probably relevant for AD243, in which phenotype and/or endotype-based stratification for selection of potential treatment responders with an optimal risk–benefit ratio represents an attractive strategy.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [243]
In the citing paper
“These factors, which include diverse environmental influences, a complex genotype, microbiome-derived signals and a dynamic immune response, also underlie the highly variable therapeutic response and adverse events to established and new compounds for AD therapy243.”
From Atopic dermatitis: an expanding therapeutic pipeline for a complex disease (2022) · cites this paper as [243]
Citations
Cites
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Beck, L. A., Thaçi, D., Hamilton, J. D., Graham, N. M., Bieber, T., Rocklin, R., Ming, J. E., Ren, H., Kao, R., Simpson, E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314768 · Cited by 1,421
The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch
Wilson, S. R., Thé, L., Batia, L. M., Beattie, K., Katibah, G. E., McClain, S. P., Pellegrino, M., Estandian, D. M., & Bautista, D. M. (2013) · Cell · doi:10.1016/j.cell.2013.08.057 · Cited by 987
Tezepelumab in Adults with Uncontrolled Asthma
Corren, J., Parnes, J. R., Wang, L., Mo, M., Roseti, S. L., Griffiths, J. M., & van der Merwe, R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704064 · Cited by 965
Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M., & Tokura, Y. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.111 · Cited by 671
Noda, S., Suárez-Fariñas, M., Ungar, B., Kim, S. J., de Guzman Strong, C., Xu, H., Peng, X., Estrada, Y. D., Nakajima, S., Honda, T., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.08.015 · Cited by 657
The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
Brunner, P. M., Guttman-Yassky, E., & Leung, D. Y. M. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.01.011 · Cited by 642
Atopic dermatitis endotypes and implications for targeted therapeutics
Czarnowicki, T., He, H., Krueger, J. G., & Guttman-Yassky, E. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.10.032 · Cited by 631
Nograles, K. E., Zaba, L. C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., Ramon, M., Bergman, R., Krueger, J. G., & Guttman-Yassky, E. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.03.041 · Cited by 627
Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
Li, H., Zuo, J., & Tang, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01048 · Cited by 580
Paller, A. S., Tom, W. L., Lebwohl, M. G., Blumenthal, R. L., Boguniewicz, M., Call, R. S., Eichenfield, L. F., Forsha, D. W., Rees, W. C., Simpson, E. L., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.05.046 · Cited by 577
Suárez-Fariñas, M., Dhingra, N., Gittler, J., Shemer, A., Cardinale, I., de Guzman Strong, C., Krueger, J. G., & Guttman-Yassky, E. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.046 · Cited by 483
Pathogenesis of psoriasis and development of treatment
Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14139 · Cited by 456
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?
Guttman-Yassky, E., & Krueger, J. G. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.08.008 · Cited by 412
Benson, J. M., Peritt, D., Scallon, B. J., Heavner, G. A., Shealy, D. J., Giles-Komar, J. M., & Mascelli, M. A. (2011) · mAbs · doi:10.4161/mabs.3.6.17815 · Cited by 340
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.059 · Cited by 328
The Primary Outcome Fails — What Next?
Pocock, S. J., & Stone, G. W. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510064 · Cited by 274
Czarnowicki, T., Gonzalez, J., Shemer, A., Malajian, D., Xu, H., Zheng, X., Khattri, S., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.020 · Cited by 221
Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Khattri, S., Brunner, P. M., Garcet, S., Finney, R., Cohen, S. R., Oliva, M., Dutt, R., Fuentes‐Duculan, J., Zheng, X., Li, X., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13112 · Cited by 214
Straumann, A., Hoesli, S., Bussmann, C., Stuck, M., Perkins, M., Collins, L. P., Payton, M., Pettipher, R., Hunter, M., Steiner, J., et al. (2013) · Allergy · doi:10.1111/all.12096 · Cited by 207
Crowley, J., Thaçi, D., Joly, P., Peris, K., Papp, K. A., Goncalves, J., Day, R. M., Chen, R., Shah, K., Ferrándiz, C., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.01.052 · Cited by 193 · cited 1×
“Moreover, neither dosage of apremilast was able to significantly reduce pruritus in patients with AD, unlike phase III trials of apremilast for moderate-to-severe plaque psoriasis [12, 13].”
BackgroundTherapeutic pipeline for atopic dermatitis: End of the drought?
Paller, A. S., Kabashima, K., & Bieber, T. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.006 · Cited by 192
Fujisawa, T., Fujisawa, R., Kato, Y., Nakayama, T., Morita, A., Katsumata, H., Nishimori, H., Iguchi, K., Kamiya, H., Gray, P. W., et al. (2002) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2002.126079 · Cited by 170 · cited 1×
“Elevated TSLP levels have been discovered in the skin lesions of patients with AD [39].”
BackgroundBaumer, W., Hoppmann, J., Rundfeldt, C., & Kietzmann, M. (2007) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152807780077318 · Cited by 162
Butler, J. M., Chan, S. C., Stevens, S. R., & Hanifin, J. M. (1983) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(83)90467-0 · Cited by 143
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Bissonnette, R., Pavel, A. B., Diaz, A., Werth, J. L., Zang, C., Vranic, I., Purohit, V. S., Zielinski, M. A., Vlahos, B., Estrada, Y. D., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.06.047 · Cited by 131
Reich, A., Riepe, C., Anastasiadou, Z., Mędrek, K., Augustin, M., Szepietowski, J. C., & Ständer, S. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2433 · Cited by 130 · cited 1×
“Even though roflumilast cream significantly decreased pruritus, the minimal clinically important difference (MCID) for itch reduction between roflumilast and the placebo group was likely not met [25, 26].”
BackgroundProstaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis
Chang, J. E., Doherty, T. A., Baum, R., & Broide, D. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.020 · Cited by 127
Kupczyk, M., & Kuna, P. (2017) · Drugs · doi:10.1007/s40265-017-0777-2 · Cited by 123
A Phase 2 Randomized Trial of Apremilast in Patients with Atopic Dermatitis
Simpson, E. L., Imafuku, S., Poulin, Y., Ungar, B., Zhou, L., Malik, K., Wen, H.-C., Xu, H., Estrada, Y. D., Peng, X., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.10.043 · Cited by 120
Saeki, H., Kabashima, K., Tokura, Y., Murata, Y., Shiraishi, A., Tamamura, R., Randazzo, B., & Imanaka, K. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15493 · Cited by 118
Cooper, K. D., Kang, K., Chan, S. C., & Hanifin, J. M. (1985) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12272486 · Cited by 102
Emerging Treatment Options in Atopic Dermatitis: Topical Therapies
Nygaard, U., Deleuran, M., & Vestergaard, C. (2017) · Dermatology · doi:10.1159/000484407 · Cited by 99
Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis
Czarnowicki, T., Malajian, D., Shemer, A., Fuentes‐Duculan, J., Gonzalez, J., Suárez‐Fariñas, M., Krueger, J. G., & Guttman‐Yassky, E. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.03.032 · Cited by 85 · cited 1×
“Patients with AD have a heightened widespread systemic activation of T cells [2, 47].”
BackgroundGottlieb, A. B., Matheson, R. T., Menter, A., Leonardi, C. L., Day, R. M., Hu, C., Schafer, P. H., & Krueger, J. G. (2013) · PubMed · Cited by 76
Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy
Kim, J., Kim, B. E., Lee, J., Han, Y., Jun, H.-Y., Kim, H., Choi, J., Leung, D. Y. M., & Ahn, K. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.12.1306 · Cited by 72
Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis
Martel, B. C., Litman, T., Hald, A., Norsgaard, H., Lovato, P., Dyring‐Andersen, B., Skov, L., Thestrup‐Pedersen, K., Skov, S., Skak, K., et al. (2016) · Experimental Dermatology · doi:10.1111/exd.12967 · Cited by 71
Mathiesen, J. M., Christopoulos, A., Ulven, T., Royer, J. F., Campillo, M., Heinemann, Á., Pardo, L., & Kostenis, E. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.017681 · Cited by 57
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
Savage, L. J., Wittmann, M., McGonagle, D., & Helliwell, P. S. (2015) · Rheumatology and Therapy · doi:10.1007/s40744-015-0010-2 · Cited by 53
Townley, R. G., & Agrawal, S. (2012) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2012.04.004 · Cited by 31
Immune mediators and therapies for pruritus in atopic dermatitis and psoriasis
Yu, S., Li, Y., Zhou, Y., Follansbee, T., & Hwang, S. T. (2019) · Journal of Cutaneous Immunology and Allergy · doi:10.1002/cia2.12049 · Cited by 31
Lee, H. H., Patel, K. R., Rastogi, S., Singam, V., Vakharia, P. P., Chopra, R., & Silverberg, J. I. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.05.102 · Cited by 31
Rosenfeld, P. J., & Feuer, W. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.06.002 · Cited by 26
Snape, S. D., Wigger‐Alberti, W., & Goehring, U.-M. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14634 · Cited by 20
Spotlight on fevipripant and its potential in the treatment of asthma: evidence to date
Kao, C. C., & Parulekar, A. D. (2019) · Journal of Asthma and Allergy · doi:10.2147/jaa.s167973 · Cited by 15
Kitzen, J. M., Pergolizzi, J. V., Taylor, R., & Raffa, R. B. (2018) · Pharmacology & Pharmacy · doi:10.4236/pp.2018.99028 · Cited by 13
Research works printed but not linked: 1
- Mease PJ, Gladman DD, Gomez-Reino JJ, Hall S, Kavanaugh A, Lespessailles E, Schett G, Paris M, Teng L, Wollenhaupt J. Consistent safety profile with up to 4 years of apremilast treatment: analysis of data from 1493 subjects with psoriatic arthritis in 3 large, phase III, long-term studies [abstract]. Arthritis Rheumatol. 2017;69:604.
Cited by
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
Bieber, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00266-6 · Cited by 623
New and Emerging Systemic Treatments for Atopic Dermatitis
Newsom, M., Bashyam, A. M., Balogh, E. A., Feldman, S. R., & Strowd, L. C. (2020) · Drugs · doi:10.1007/s40265-020-01335-7 · Cited by 136
Itch: Pathogenesis and treatment
Sutaria, N., Adawi, W., Goldberg, R., Roh, Y. S., Choi, J., & Kwatra, S. G. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.078 · Cited by 130
Meng, J., Li, Y., Fischer, M. J. M., Steinhoff, M. S., Chen, W., & Wang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.696784 · Cited by 117
Agache, I. O., Akdiş, C. A., Akdiş, M., Brockow, K., Chivato, T., Giacco, S. D., Eiwegger, T., Eyerich, K., Giménez‐Arnau, A. M., Gutermuth, J., et al. (2020) · Allergy · doi:10.1111/all.14690 · Cited by 56
Metadata
- Authors
- Agnihotri, G., & Lio, P. A.
- Affiliations
- University of Illinois Chicago (US)
- Northwestern University (US)
- Corresponding author
- Lio, Peter A.
- ORCID
- Lio, Peter A.
- Venue
- Clinical Drug Investigation
- Published
- 2020-03-14
- Volume
- 40
- Issue
- 5
- Pages
- 421-431
- ISSN
- 0114-2402 (ISSN-L)
- 1173-2563
- 1179-1918
- OpenAlex
- W3011685038
- Cited by
- 15
- References
- 47
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 6 · 2020: 2
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Clinical Drug Investigation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- atopic dermatitis, clinical trial failure, drug development, apremilast, roflumilast, phosphodiesterase-4 inhibitors, fevipiprant, tezepelumab, ustekinumab, monoclonal antibodies, subgroup analysis, mechanism of action
- MeSH terms
- Clinical Trials as Topic, Dermatitis, Atopic, Dermatologic Agents, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.